Nanovibronix (NASDAQ:FEED) Insider Christian Michael Glibert Sells 210,000 Shares of Stock

Nanovibronix, Inc. (NASDAQ:FEED) insider Christian Michael Glibert sold 210,000 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $0.69, for a total transaction of $144,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Nanovibronix Price Performance

FEED opened at $0.70 on Tuesday. The company has a market cap of $4.26 million, a P/E ratio of -0.08 and a beta of 1.52. The firm’s 50-day moving average is $1.09. Nanovibronix, Inc. has a 52 week low of $0.63 and a 52 week high of $17.40.

Nanovibronix (NASDAQ:FEED) last issued its earnings results on Monday, May 18th. The company reported ($6.88) earnings per share (EPS) for the quarter. Nanovibronix had a negative return on equity of 54.25% and a negative net margin of 923.20%.The firm had revenue of $0.65 million during the quarter.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nanovibronix in a research report on Friday, April 24th. Wall Street Zen upgraded shares of Nanovibronix from a “strong sell” rating to a “sell” rating in a research report on Tuesday, April 28th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

About Nanovibronix

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.